Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696

OBJECTIVES: The combined neprilysin/rennin-angiotensin system inhibitor sacubitril/valsartan (LCZ696) has shown its superiority over ACEI/ARB therapy. In view of the existing concern of its adverse effects, we aimed to provide evidence of the safety of the new drug. RESULTS: A total of 6 randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bo, Zhao, Yunhe, Yin, Bo, Helian, Mengfei, Wang, Xinmei, Chen, Feng, Zhang, Hongxia, Sun, Hui, Meng, Bin, An, Fengshuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669972/
https://www.ncbi.nlm.nih.gov/pubmed/29137346
http://dx.doi.org/10.18632/oncotarget.18312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669972/
https://www.ncbi.nlm.nih.gov/pubmed/29137346
http://dx.doi.org/10.18632/oncotarget.18312

Ejemplares similares